Protalix BioTherapeutics Inc (AMEX:PLX) price on Friday, March 21, rose 5.51% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.49.
A look at the stock’s price movement, the close in the last trading session was $2.36, moving within a range at $2.3 and $2.49. The beta value (5-Year monthly) was 0.725 while the PE ratio in trailing twelve months stood at 94.68. Turning to its 52-week performance, $2.76 and $0.82 were the 52-week high and 52-week low respectively. Overall, PLX moved 2.47% over the past month.
Protalix BioTherapeutics Inc’s market cap currently stands at around $194.30 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-16.
Analysts have a consensus estimate of 21.6M for the company’s revenue for the quarter, with a low and high estimate of 21.6M and 21.6M respectively. The average forecast suggests up to a 487.44% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 80.49M, representing a 50.73% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that PLX is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
PLX’s current price about 6.82% and 4.28% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 57.52, while 7-day volatility ratio is 9.74% and 5.43% in the 30-day chart. Further, Protalix BioTherapeutics Inc (PLX) has a beta value of 0.50, and an average true range (ATR) of 0.15.
If we refocus on Protalix BioTherapeutics Inc (AMEX:PLX), historical trading data shows that trading volumes averaged 0.98 over the past 10 days and 682.68K over the past 3 months. The company’s latest data on shares outstanding shows there are 75.85 million shares.
The 7.51% of Protalix BioTherapeutics Inc’s shares are in the hands of company insiders while institutional holders own 6.63% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 5.05 million on 2025-02-28, giving us a short ratio of 8.4. The data shows that as of 2025-02-28 short interest in Protalix BioTherapeutics Inc (PLX) stood at 718.0000000000001 of shares outstanding, with shares short rising to 4.3 million registered in 2025-01-31. Current price change has pushed the stock 32.45% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PLX stock continues to rise going into the next quarter.
